Thrombotic microangiopathy (TMA) is a syndrome in which damage to the inner lining of small blood vessels triggers tiny blood clots throughout the body, leading to three hallmark problems: a drop in platelet count, destruction of red blood cells as they squeeze past those clots, and organ damage from reduced blood flow. It is not a single disease but rather a pattern that can result from several different underlying causes, some genetic and some acquired. Understanding which type of TMA a person has is critical because treatments differ dramatically.
How TMA Develops in the Body
The process starts with injury to endothelial cells, the thin layer of cells that lines every blood vessel. Under normal conditions, these cells produce nitric oxide, a molecule that keeps vessels relaxed, prevents inflammation, and discourages clot formation. Nitric oxide also blocks the release of proteins like von Willebrand factor and P-selectin, which would otherwise attract platelets and kick off clotting.
When something damages or activates endothelial cells, that protective system breaks down. The injured cells release von Willebrand factor and other sticky proteins, platelets latch on and clump together, and fibrin (the mesh-like protein in clots) deposits inside tiny vessels. These microclots narrow or block capillaries and small arteries, especially in the kidneys and brain. Red blood cells trying to pass through the narrowed vessels get physically sheared into fragments called schistocytes. Meanwhile, platelets are consumed faster than the body can replace them, causing the low platelet count that shows up on blood tests.
The Three Hallmarks of TMA
Doctors look for a specific triad when suspecting TMA:
- Microangiopathic hemolytic anemia (MAHA): Red blood cells are mechanically torn apart inside damaged vessels, causing anemia. A blood smear showing schistocytes above 1% of red blood cells is the threshold that supports a TMA diagnosis.
- Consumptive thrombocytopenia: Platelets are used up forming microclots, so platelet counts drop, sometimes severely.
- Organ injury: Blocked small vessels starve tissues of oxygen. The kidneys are the most commonly affected organs, but the brain, heart, gut, and other organs can also be involved.
Lab tests typically show elevated markers of red blood cell destruction (high LDH, low haptoglobin) alongside the low platelet count and rising creatinine if the kidneys are involved.
Types and Causes of TMA
TMA is an umbrella term. The specific cause determines how serious the condition is and how it’s treated.
Thrombotic Thrombocytopenic Purpura (TTP)
TTP occurs when the body lacks adequate activity of an enzyme called ADAMTS13, which normally trims ultra-large strands of von Willebrand factor so they don’t attract too many platelets. In TTP, ADAMTS13 activity falls below 10% of normal. This can happen because the immune system produces antibodies against the enzyme (acquired TTP) or, rarely, because of an inherited gene mutation. Without functioning ADAMTS13, long strands of von Willebrand factor accumulate and trigger widespread platelet clumping, particularly in the brain and kidneys. Before modern treatment existed, TTP was fatal in over 90% of cases.
Hemolytic Uremic Syndrome (HUS)
The most common form, especially in children, is caused by infection with Shiga toxin-producing bacteria like E. coli O157:H7. The toxin directly damages endothelial cells, triggers release of ultra-large von Willebrand factor, and impairs ADAMTS13 activity. This type typically follows a bout of bloody diarrhea and is the leading cause of acute kidney injury in young children, with an incidence of about 6 per 100,000 children under age 5 in Western countries. Around 71% to 77% of children with HUS develop acute kidney failure during the episode, with peak creatinine levels averaging 3.7 to 4.6 mg/dL.
Atypical HUS (Complement-Mediated TMA)
This form results from uncontrolled activation of the complement system, a branch of the immune system that normally helps clear infections but can damage the body’s own blood vessels when left unchecked. Mutations in genes encoding complement regulatory proteins, most commonly Factor H, are the primary driver. Mutations in Factor I and membrane cofactor protein have also been identified. Because the complement system is chronically dysregulated, atypical HUS tends to relapse and carries a high risk of permanent kidney damage.
Secondary TMA
A wide range of triggers can cause TMA without the specific enzyme or complement defects seen in TTP or HUS. The most common secondary causes include medications, pregnancy, malignant hypertension, autoimmune diseases, infections, organ transplantation, and cancer. Among drug-related cases, calcineurin inhibitors (used after organ transplants) account for roughly 68%, followed by the chemotherapy drug gemcitabine at 8% and VEGF inhibitors at 3%. Other implicated drugs include certain cancer therapies like proteasome inhibitors. In secondary TMA, treating or removing the underlying trigger is often the first step.
How TMA Is Diagnosed
Diagnosis starts with blood work showing the classic triad: low platelets, anemia with schistocytes on the blood smear, and evidence of organ damage. The next and most important step is figuring out the specific cause, because TTP requires emergency treatment that differs completely from the approach for complement-mediated TMA.
ADAMTS13 activity testing is the key differentiator. A level below 10% of normal points to TTP. A level above 20% makes TTP unlikely and prompts investigation of HUS, complement-mediated TMA, or secondary causes. Results between 10% and 20% fall in a gray zone that requires clinical judgment. Because ADAMTS13 results can take days to return, treatment for suspected TTP often begins immediately while awaiting confirmation.
For suspected atypical HUS, complement studies and genetic testing can identify mutations in Factor H, Factor I, and related proteins. Stool cultures or toxin assays help identify Shiga toxin-producing bacterial infections in typical HUS.
Treatment by TMA Type
Treatment depends entirely on the underlying cause, which is why rapid diagnosis matters so much.
For TTP, the cornerstone is therapeutic plasma exchange, which physically removes the antibodies attacking ADAMTS13 and replaces the missing enzyme. This treatment transformed TTP from a condition with over 90% mortality to one where 80% to 90% of patients survive. Immune-suppressing medications are added to stop antibody production, and newer targeted therapies can block the interaction between von Willebrand factor and platelets.
For complement-mediated atypical HUS, treatment targets the overactive complement system. A complement-blocking medication is given intravenously, typically weekly for the first four weeks and then every two weeks for maintenance. Blood levels of the drug are monitored, particularly in the first week, to ensure the complement system is adequately suppressed. Patients receiving this type of therapy need vaccination against certain bacteria because blocking complement increases susceptibility to specific infections.
For typical HUS caused by Shiga toxin, treatment is mainly supportive: fluids, blood transfusions, and dialysis if kidney function drops too low. Antibiotics are generally avoided because killing the bacteria can release more toxin. Most children recover kidney function, though some develop lasting damage.
For secondary TMA, the priority is addressing the trigger. That might mean stopping an offending medication, controlling severe blood pressure, delivering a baby in pregnancy-related cases, or treating an underlying autoimmune condition.
Long-Term Kidney Outcomes
The kidneys bear the brunt of TMA in most forms. Small vessel clots in the kidneys can cause acute failure that requires temporary dialysis, but the long-term picture varies widely by cause. In one study of patients with TMA related to severe hypertension who initially avoided dialysis, about 31% still progressed to end-stage kidney disease over a median follow-up of roughly two years, eventually requiring chronic dialysis or transplantation.
Children with Shiga toxin-associated HUS generally have the best kidney prognosis, with most recovering function, though a subset develops chronic kidney disease, high blood pressure, or protein in the urine years later. Atypical HUS carries a higher risk of kidney loss, particularly when complement-blocking treatment is delayed or when certain genetic mutations (especially Factor H) are present. Ongoing monitoring of kidney function, blood pressure, and urine protein is standard for anyone who has experienced a TMA episode, regardless of the cause.